Phentermine and Topiramate Extended-release: a New Treatment for Obesity and Its Role in a Complications-centric Approach to Obesity Medical Management

Overview

Journal Expert Opin Drug Saf

Specialty Pharmacology

Date 2013 Jun 7

PMID 23738843

Citations 9

Authors

William Timothy Garvey

Affiliations

Soon will be listed here.

Abstract

Introduction: Weight-management options include lifestyle modifications, bariatric surgery and, until recently, limited pharmacotherapy. Phentermine and topiramate extended-release (phentermine/topiramate ER) has recently been approved in the USA for chronic weight management in obese adults and overweight adults with weight-related co-morbidities in conjunction with a reduced-calorie diet and increased physical activity.

Areas Covered: This review describes the pharmacology and clinical trials data for phentermine/topiramate ER and its role in a complications-centric approach to medical care of the overweight and obese patient.

Expert Opinion: Phentermine/topiramate ER is an effective and safe weight-loss medication that can produce and sustain approximately 10% loss of body weight. This is a landmark development in the pharmacotherapy of obesity. By offering an effective medical option to complement lifestyle and surgical approaches, phentermine/topiramate ER enables a comprehensive medical model for obesity care. The overall approach to the overweight and obese patient should be to identify individuals who will benefit most from therapy based on cardiometabolic or mechanical complications, establish therapeutic targets and goals for ameliorating these complications and selecting the treatment modality and intensity for weight loss to achieve these goals. This complications-centric model emphasizes weight loss as a tool to ameliorate obesity-related complications and optimizes benefit/risk for achieving the best outcomes in overweight/obese patients.

Citing Articles

Strengths and Limitations of BMI in the Diagnosis of Obesity: What is the Path Forward?.

Sweatt K, Garvey W, Martins C Curr Obes Rep. 2024; 13(3):584-595.

PMID: 38958869 PMC: 11306271. DOI: 10.1007/s13679-024-00580-1.

Catalytic intramolecular aminoarylation of unactivated alkenes with aryl sulfonamides.

Noten E, McAtee R, Stephenson C Chem Sci. 2022; 13(23):6942-6949.

PMID: 35774166 PMC: 9200115. DOI: 10.1039/d2sc01228f.

Weight maintenance: challenges, tools and strategies for primary care physicians.

Soleymani T, Daniel S, Garvey W Obes Rev. 2015; 17(1):81-93.

PMID: 26490059 PMC: 4715703. DOI: 10.1111/obr.12322.

2014 EASO Position Statement on the Use of Anti-Obesity Drugs.

Toplak H, Woodward E, Yumuk V, Oppert J, Halford J, Fruhbeck G Obes Facts. 2015; 8(3):166-74.

PMID: 25968960 PMC: 5644876. DOI: 10.1159/000430801.

Amphetamine-Like Analogues in Diabetes: Speeding towards Ketogenesis.

Branis N, Wittlin S Case Rep Endocrinol. 2015; 2015:917869.

PMID: 25960894 PMC: 4417573. DOI: 10.1155/2015/917869.

References

Gadde K, Allison D, Ryan D, Peterson C, Troupin B, Schwiers M . Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9774):1341-52. DOI: 10.1016/S0140-6736(11)60205-5. View

Tuomilehto H, Seppa J, Partinen M, Peltonen M, Gylling H, Tuomilehto J . Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med. 2008; 179(4):320-7. DOI: 10.1164/rccm.200805-669OC. View

Chowdhuri S . Continuous positive airway pressure for the treatment of sleep apnea. Otolaryngol Clin North Am. 2007; 40(4):807-27. DOI: 10.1016/j.otc.2007.04.011. View

Bray G, Ryan D . Medical therapy for the patient with obesity. Circulation. 2012; 125(13):1695-703. DOI: 10.1161/CIRCULATIONAHA.111.026567. View

Wadden T, Berkowitz R, Womble L, Sarwer D, Phelan S, Cato R . Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005; 353(20):2111-20. DOI: 10.1056/NEJMoa050156. View

Pi-Sunyer X, Blackburn G, Brancati F, Bray G, Bright R, Clark J . Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007; 30(6):1374-83. PMC: 2665929. DOI: 10.2337/dc07-0048. View

Heber D, Greenway F, Kaplan L, Livingston E, Salvador J, Still C . Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010; 95(11):4823-43. DOI: 10.1210/jc.2009-2128. View

Promrat K, Kleiner D, Niemeier H, Jackvony E, Kearns M, Wands J . Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2009; 51(1):121-9. PMC: 2799538. DOI: 10.1002/hep.23276. View

Schmier J, Jones M, Halpern M . Cost of obesity in the workplace. Scand J Work Environ Health. 2006; 32(1):5-11. DOI: 10.5271/sjweh.970. View

10.

Makowski C, Gwinn K, Hurren K . Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obes Facts. 2012; 4(6):489-94. PMC: 6444555. DOI: 10.1159/000335352. View

11.

Christensen R, Bartels E, Astrup A, Bliddal H . Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2007; 66(4):433-9. PMC: 1856062. DOI: 10.1136/ard.2006.065904. View

12.

. Standards of medical care in diabetes--2013. Diabetes Care. 2012; 36 Suppl 1:S11-66. PMC: 3537269. DOI: 10.2337/dc13-S011. View

13.

Reaven G . Importance of identifying the overweight patient who will benefit the most by losing weight. Ann Intern Med. 2003; 138(5):420-3. DOI: 10.7326/0003-4819-138-5-200303040-00012. View

14.

. Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008; 31(3):596-615. DOI: 10.2337/dc08-9017. View

15.

James W, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A . Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010; 363(10):905-17. DOI: 10.1056/NEJMoa1003114. View

16.

Kolotkin R, Meter K, Williams G . Quality of life and obesity. Obes Rev. 2002; 2(4):219-29. DOI: 10.1046/j.1467-789x.2001.00040.x. View

17.

Wildman R, Muntner P, Reynolds K, McGinn A, Rajpathak S, Wylie-Rosett J . The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008; 168(15):1617-24. DOI: 10.1001/archinte.168.15.1617. View

18.

Sjostrom L, Gummesson A, Sjostrom C, Narbro K, Peltonen M, Wedel H . Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009; 10(7):653-62. DOI: 10.1016/S1470-2045(09)70159-7. View

19.

Bluher M . Are there still healthy obese patients?. Curr Opin Endocrinol Diabetes Obes. 2012; 19(5):341-6. DOI: 10.1097/MED.0b013e328357f0a3. View

20.

Winslow D, Bowden C, DiDonato K, McCullough P . A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep. 2012; 35(11):1529-39. PMC: 3466800. DOI: 10.5665/sleep.2204. View